Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ide-cel

    - PMLiVE

    BMS and 2seventy’s multiple myeloma therapy Abecma receives expanded FDA approval

    More than 35,700 new cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    Bristol Myers Squibb announces EC approval for multiple myeloma therapy Abecma

    Approximately 50,000 cases of the blood cancer are diagnosed in Europe every year

    regeneron headquarters

    Regeneron to acquire 2seventy’s investigational cell therapy pipeline

    An estimated 150 2seventy employees will join Regeneron’s new research and development unit

    - PMLiVE

    Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer

    More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

    - PMLiVE

    BMS announces CHMP recommendation for multiple myeloma therapy Abecma

    More than 50,000 cases of the blood cancer are diagnosed in Europe every year

    - PMLiVE

    BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

    More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

    - PMLiVE

    BMS presents promising late-stage results for Opdivo plus Yervoy in colorectal cancer

    More than 1.9 million cases of colorectal cancer were diagnosed globally in 2020

    - PMLiVE

    Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma

    More than 16,700 new cases of melanoma are diagnosed in the UK every year

    - PMLiVE

    Bristol Myers Squibb to acquire radiopharmaceutical specialist RayzeBio for $4.1bn

    The merger includes a candidate in phase 3 development for gastroenteropancreatic neuroendocrine tumours

    - PMLiVE

    Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

    Approximately 17,000 cases of melanoma are diagnosed in the UK every year

    - PMLiVE

    Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

    More than 133,520 people in Scotland are affected by the inflammatory condition

    - PMLiVE

    FDA approves two cell-based gene therapies for sickle cell disease

    Vertex/CRISPR and bluebird bio’s gene therapies have been approved to treat patients aged 12 years and older

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links